Key result
Finerenone cuts CV mortality ~16% and reduces heart failure risk in CKD and T2D.
Why the study?
Recent studies have examined finerenone to reduce cardiorenal events alongside renin-angiotensin system blockers, motivating a meta-analysis to evaluate its effects on cardiorenal outcomes and serum potassium in patients with type 2 diabetes mellitus and chronic kidney disease.
Does finerenone reduce cardiovascular mortality and heart failure in patients with chronic kidney disease and type 2 diabetes?
Meta-Analysis (n=15,462)
Does finerenone reduce cardiovascular mortality and heart failure in patients with chronic kidney disease and type 2 diabetes?
Finerenone reduces the risk of cardiovascular mortality and heart failure in patients with chronic kidney disease and type 2 diabetes, though it increases the risk of moderate hyperkalemia.
Answers are grounded in this paper and cite their sources.
Supports finerenone for CV risk reduction in CKD-T2D; reinforces RCT evidence despite hyperkalemia trade-off.
Background and objectives: The incidence of morbidity and mortality in patients with type 2 diabetes mellitus is substantially correlated with cardiovascular disease and chronic kidney disease. The current guidelines recommend the use of renin-angiotensin system blockers, but recent studies probed into the effects of finerenone to mitigate the risk of cardiorenal events. This meta-analysis was performed to demonstrate the effects of finerenone on cardiorenal events, comprising cardiovascular mortality, heart failure, change in estimated glomerular filtration rate, and serum potassium levels. Methods: After screening with our eligibility criteria, 350 articles were identified with an initial literature search on multiple databases, including PubMed, Science Direct, and Cochrane Central. Seven randomized controlled trials with a total of 15 462 patients ( n =8487 in the finerenone group; n =6975 in the control group) were included. Results: Patients receiving finerenone were at a reduced risk for cardiovascular mortality [HR: 0.84 (0.74, 0.95)], heart failure [OR: 0.79 (0.68, 0.92)], decrease in estimated glomerular filtration rate by 40% [OR: 0.82 (0.74, 0.91)] and by 57% [OR: 0.70 (0.59, 0.82)]; and a higher incidence of moderate hyperkalemia [OR: 2.25 (1.78, 2.84)]. Conclusion: Finerenone, owing to its better mineralocorticoid affinity, and a much lower risk of adverse effects, promises to be a much better alternative than other renin-angiotensin system blockers available for the treatment of chronic kidney disease patients with type 2 diabetes. Further trials should be conducted to provide more definitive evidence to assess the safety and efficacy of finerenone compared to spironolactone and eplerenone.
No takes yet. Share an insight, caveat, or question.
Yasmin et al. (2023) conducted a meta-analysis in chronic kidney disease and type 2 diabetes (n=15,462). finerenone vs. control was evaluated on cardiovascular mortality (HR 0.84, 95% CI 0.74, 0.95). Finerenone reduced the risk of cardiovascular mortality and heart failure in patients with chronic kidney disease and type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: